Lamivudine News
FDA Approves New Treatment for Chronic Hepatitis B in Adults
The Food and Drug Administration (FDA) today approved Tyzeka (telbivudine) for the treatment of adults with chronic hepatitis B (HBV), a serious viral infection that attacks the liver and can cause lifelong infection, scarring of...
Indian firm gets US nod for anti-AIDS cocktail pill
In the first tentative approval of its kind, the US Food and Drug Administration (FDA) has given the go-ahead to an Indian pharmaceutical firm for a three-ingredient fixed dose anti-AIDS cocktail pill for adults.
Three-Component AIDS Drug Given Tentative FDA Approval
The FDA within the Department of Health and Human Services (HHS) recently issued the first tentative approval for a three-ingredient fixed dose tablet for use as a stand-alone antiretroviral treatment for human immunodeficiency...
FDA approves once-daily Epivir
Epivir (lamivudine) can now be taken once a day. The U.S. Food and Drug Administration (FDA) in June approved a dose of 300 mg once a day.
Lamivudine resistance common in patients coinfected with hepatitis B and HIV
Lamivudine resistance mutations are common in patients coinfected with HIV and hepatitis B virus (HBV), according to a report in the April 4th issue of AIDS.
Displaying results 6 to 10 out of 12